|
|
吡美莫司乳膏维持治疗特应性皮炎的临床研究
|
Abstract:
目的：评价吡美莫司在特应性皮炎维持治疗中的作用。方法：74例AD病变缓解的患者随机接受1%吡美莫司乳膏或润肤剂4周的治疗。在研究结束时测量所有随机患者的湿疹面积和严重程度指数，评估复发率。结果：在研究结束时，复发患者吡美莫司乳膏治疗组中占24.3% (9/37)，而在润肤剂组中占62.2% (23/37)，差异有统计学意义。两组间均无不良反应发生。结论：局部外用吡美莫司能够抑制皮肤炎症浸润复发，可有效维持AD缓解，安全性较好。
Objective: To evaluate the efficacy of pimecrolimus in maintenance therapy for atopic dermatitis. Method: 74 patients with relieved AD were randomly treated with 1% pimecrolimus cream or moisturizer for 4 weeks. Measure the eczema area and severity index of all randomized patients at the end of the study to evaluate the recurrence rate. Result: At the end of the study, 24.3% (9/37) of recurrent patients were treated with pimecrolimus cream, while 62.2% (23/37) were treated with moisturizer, with a statistically significant difference. No adverse reactions occurred between the two groups. Conclusion: Topical application of pimecrolimus can inhibit the infiltration and recurrence of skin inflammation, effectively maintain AD remission, and have fewer adverse reactions.
| [1] | Weidinger, S. and Novak, N. (2016) Atopic Dermatitis. The Lancet, 387, 1109-1122. https://doi.org/10.1016/s0140-6736(15)00149-x |
| [2] | 中华医学会, 中华医学会杂志社, 中华医学会皮肤性病学分会, 等. 特应性皮炎基层诊疗指南(2022年) [J]. 中华全科医师杂志, 2022, 21(7): 609-619. |
| [3] | 申晨, 陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445. |
| [4] | Hamid, Q., Boguniewicz, M. and Leung, D.Y. (1994) Differential in Situ Cytokine Gene Expression in Acute versus Chronic Atopic Dermatitis. Journal of Clinical Investigation, 94, 870-876. https://doi.org/10.1172/jci117408 |
| [5] | Bieber, T. (2008) Atopic Dermatitis. New England Journal of Medicine, 358, 1483-1494. https://doi.org/10.1056/nejmra074081 |
| [6] | Mihm, M.C., Soter, N.A., Dvorak, H.F. and Austen, K.F. (1976) The Structure of Normal Skin and the Morphology of Atopic Eczema. Journal of Investigative Dermatology, 67, 305-312. https://doi.org/10.1111/1523-1747.ep12514346 |
| [7] | Abuabara, K., Margolis, D.J. and Langan, S.M. (2017) The Long-Term Course of Atopic Dermatitis. Dermatologic Clinics, 35, 291-297. https://doi.org/10.1016/j.det.2017.02.003 |
| [8] | Li, H., Zhang, Z., Zhang, H., Guo, Y. and Yao, Z. (2021) Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clinical Reviews in Allergy & Immunology, 61, 324-338. https://doi.org/10.1007/s12016-021-08880-3 |
| [9] | Leung, D.Y.M., Boguniewicz, M., Howell, M.D., Nomura, I. and Hamid, Q.A. (2004) New Insights into Atopic Dermatitis. Journal of Clinical Investigation, 113, 651-657. https://doi.org/10.1172/jci200421060 |
| [10] | Hoetzenecker, W., Ecker, R., Kopp, T., Stuetz, A., Stingl, G. and Elbe-Bürger, A. (2005) Pimecrolimus Leads to an Apoptosis-Induced Depletion of T Cells but Not Langerhans Cells in Patients with Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 115, 1276-1283. https://doi.org/10.1016/j.jaci.2005.02.011 |
| [11] | Bangert, C., Strober, B.E., Cork, M., Ortonne, J., Luger, T., Bieber, T., et al. (2010) Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. Dermatology, 222, 36-48. https://doi.org/10.1159/000321711 |
| [12] | Stuetz, A., Baumann, K., Grassberger, M., Wolff, K. and Meingassner, J.G. (2006) Discovery of Topical Calcineurin Inhibitors and Pharmacological Profile of Pimecrolimus. International Archives of Allergy and Immunology, 141, 199-212. https://doi.org/10.1159/000095289 |
| [13] | Jensen, J., Pfeiffer, S., Witt, M., Bräutigam, M., Neumann, C., Weichenthal, M., et al. (2009) Different Effects of Pimecrolimus and Betamethasone on the Skin Barrier in Patients with Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 124, R19-R28. https://doi.org/10.1016/j.jaci.2009.07.015 |
